Onxeo has engaged MCT (Regional CRO specialized on Middle East and Africa) to expand “Relieve” phase III HCC study in 3 Middle East countries (Lebanon, Egypt and Saudi Arabia). More information in Onxeo press release: 150326EN_Livatag
Related Posts
MCT Team at OCT New England in Boston
News / November 6, 2018
NLV Study – The Noguchi MIMR Site
News / July 30, 2021